 |
Top 7 Rheumatoid Arthritis treatment startups in USA
Oct 12, 2024 | By Jason Kwon | 26 |
1
Funding: $637M
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
2
Funding: $558M
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
3
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
4
Funding: $344M
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
5
Funding: $327.6M
AltruBio develops antibody-targeted therapies for psoriatic arthritis and ulcerative colitis
AltruBio develops antibody-targeted therapies for psoriatic arthritis and ulcerative colitis
6
Funding: $92.3M
GRO Biosciences is a biotechnology company that expands the amino acid alphabet to overcome the limitations of protein therapeutics.
GRO Biosciences is a biotechnology company that expands the amino acid alphabet to overcome the limitations of protein therapeutics.
7
Funding: $70M
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
